🇺🇸 FDA
Patent

US 6348466

CRF receptor antagonists and methods relating thereto

expired A61PA61P1/00A61P1/14

Quick answer

US patent 6348466 (CRF receptor antagonists and methods relating thereto) held by Neurocrine Biosciences, Inc. expires Mon Feb 14 2022 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.

Key facts

Applicant
Neurocrine Biosciences, Inc.
Grant date
Tue Feb 19 2002 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 14 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61P, A61P1/00, A61P1/14, A61P25/00, A61P25/08